<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
   <journal-meta>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
      <journal-id journal-id-type="pmc">ploscomp</journal-id>
      <journal-title-group>
         <journal-title>PLoS Computational Biology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1553-734X</issn>
      <issn pub-type="epub">1553-7358</issn>
      <publisher>
         <publisher-name>Public Library of Science</publisher-name>
         <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
   </journal-meta>
   <article-meta>
      <article-id pub-id-type="publisher-id">PCOMPBIOL-D-12-01331</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pcbi.1003016</article-id>
      <article-categories>
         <subj-group subj-group-type="heading">
            <subject>Research Article</subject>
         </subj-group>
<subj-group subj-group-type="Discipline-v2"><subject>Biology</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject>
</subj-group>
      </article-categories>
      <title-group>
         <article-title>Synthetic Lethality between Gene Defects Affecting a Single Non-essential Molecular Pathway with Reversible Steps</article-title>
         <alt-title alt-title-type="running-head">Within-reversible-pathway Synthetic Lethality</alt-title>
      </title-group>
      <contrib-group>
         <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
            <name name-style="western"><surname>Zinovyev</surname><given-names>Andrei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref>
         </contrib>
         <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
            <name name-style="western"><surname>Kuperstein</surname>
<given-names>Inna</given-names>
            </name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
         </contrib>
         <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western"><surname>Barillot</surname>
<given-names>Emmanuel</given-names>
            </name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
         </contrib>
         <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western"><surname>Heyer</surname><given-names>Wolf-Dietrich</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref>
         </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label><addr-line>Institut Curie, Paris, France</addr-line></aff>
      <aff id="aff2"><label>2</label><addr-line>INSERM, U900, Paris, France</addr-line></aff>
      <aff id="aff3"><label>3</label><addr-line>Mines ParisTech, Fontainebleau, France</addr-line></aff>
      <aff id="aff4"><label>4</label><addr-line>Departments of Microbiology &amp; Molecular Genetics and of Molecular &amp; Cellular Biology, University of California, Davis, Davis, California, United States of America</addr-line></aff>
      <contrib-group>
         <contrib contrib-type="editor" xlink:type="simple">
            <name name-style="western"><surname>Roth</surname>
<given-names>Frederick P.</given-names>
            </name><role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
         </contrib>
      </contrib-group>
      <aff id="edit1"><addr-line>University of Toronto and Mount Sinai Hospital, Canada</addr-line></aff>
      <author-notes>
         <corresp id="cor1">* E-mail: <email xlink:type="simple">Andrei.Zinovyev@curie.fr</email> (AZ); <email xlink:type="simple">wdheyer@ucdavis.edu</email> (WDH)</corresp>
         <fn fn-type="conflict">
            <p>The authors have declared that no competing interests exist.</p>
         </fn>
         <fn fn-type="con">
            <p>Conceived and designed the experiments: AZ IK WDH. Performed the experiments: AZ. Analyzed the data: AZ IK EB WDH. Wrote the paper: AZ IK EB WDH.</p>
         </fn>
      </author-notes>
      <pub-date pub-type="collection">
         <month>4</month>
         <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
         <day>4</day>
         <month>4</month>
         <year>2013</year>
      </pub-date>
      <volume>9</volume>
      <issue>4</issue>
      <elocation-id>e1003016</elocation-id>
      <history>
         <date date-type="received">
            <day>21</day>
            <month>8</month>
            <year>2012</year>
         </date>
         <date date-type="accepted">
            <day>18</day>
            <month>2</month>
            <year>2013</year>
         </date>
      </history>
      <permissions>
         <copyright-year>2013</copyright-year>
         <copyright-holder>Zinovyev et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
      <abstract>
         <p>Systematic analysis of synthetic lethality (SL) constitutes a critical tool for systems biology to decipher molecular pathways. The most accepted mechanistic explanation of SL is that the two genes function in parallel, mutually compensatory pathways, known as between-pathway SL. However, recent genome-wide analyses in yeast identified a significant number of within-pathway negative genetic interactions. The molecular mechanisms leading to within-pathway SL are not fully understood. Here, we propose a novel mechanism leading to within-pathway SL involving two genes functioning in a single non-essential pathway. This type of SL termed within-reversible-pathway SL involves reversible pathway steps, catalyzed by different enzymes in the forward and backward directions, and kinetic trapping of a potentially toxic intermediate. Experimental data with recombinational DNA repair genes validate the concept. Mathematical modeling recapitulates the possibility of kinetic trapping and revealed the potential contributions of synthetic, dosage-lethal interactions in such a genetic system as well as the possibility of within-pathway positive masking interactions. Analysis of yeast gene interaction and pathway data suggests broad applicability of this novel concept. These observations extend the canonical interpretation of synthetic-lethal or synthetic-sick interactions with direct implications to reconstruct molecular pathways and improve therapeutic approaches to diseases such as cancer.</p>
      </abstract>
      <abstract abstract-type="summary">
         <title>Author Summary</title>
         <p>Organizing gene functions into molecular pathways is a major challenge in biology. The observation that two viable gene mutations become lethal when combined as a double mutant has been developed into a major genetic tool called synthetic lethality. The classic interpretation of synthetic lethality stipulates that the two mutations identify genes that work in parallel, mutually compensatory pathways that together perform an essential function. However, a significant number of negative interactions are caused by defects affecting a single molecular pathway. Here, we recapitulate by mathematical modeling recent experimental data that demonstrate synthetic lethality between mutations in genes acting in a single, non-essential molecular pathway. We propose a novel mechanism involving reversible pathways steps and trapping of an intermediate. The modeling also predicts that overexpression of certain genes functioning in reversible pathways will lead to synthetic lethality with gene defects in the same pathway. Our results significantly broaden the interpretation of synthetic lethal and synthetic dosage effects, which fundamentally impacts the assignment of genes to pathways. The concept of synthetic lethality has been applied to cancer therapy, and our modeling results suggest new approaches to how to target a single pathway to induce synthetic lethality in cancer cells.</p>
      </abstract>
      <funding-group>
         <funding-statement>AZ, IK and EB are members of the team “Computational Systems Biology of Cancer,” Equipe labellisée par la Ligue Nationale Contre le Cancer. The study was also supported by funding to WDH from the Rothschild-Yvette Mayent Fund, NIH (CA92276, GM58015, CA154920). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
      </funding-group>
<counts>
<page-count count="12"/>
</counts>
</article-meta>
</front>
<body>
   <sec id="s1">
      <title>Introduction</title>
      <p>Synthetic interactions between two mutations in different genes were first revealed in <italic>Drosophila</italic> by Dobzhansky in the 1940s <xref ref-type="bibr" rid="pcbi.1003016-Dobzhansky1">[1]</xref>. Synthetic lethality (SL) describes that two viable single gene mutations lead to lethality (synthetic-lethal) or severely impair growth (synthetic-sick) when combined as a double mutant. This concept was implemented as a powerful research tool for molecular pathway analysis in yeast <xref ref-type="bibr" rid="pcbi.1003016-Collins1">[2]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Costanzo1">[5]</xref>. Further refinement introduced more quantitative measures of genetic epistasis <xref ref-type="bibr" rid="pcbi.1003016-Boone1">[6]</xref> and lethality induced by gene overexpression in a mutant background (synthetic dosage-lethality <xref ref-type="bibr" rid="pcbi.1003016-Kroll1">[7]</xref>). A genetic interaction is negative or aggravating, when the combined effect of two gene defects is more severe than it is expected from a simple multiplicative model. In a positive or alleviating interaction the effect is less severe than expected. These approaches and measures are now increasingly used in mammalian cells exploiting RNA-mediated gene knockdown technologies <xref ref-type="bibr" rid="pcbi.1003016-Silva1">[8]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Iorns1">[9]</xref>.</p>
      <p>Following a proposal by Hartwell and colleagues <xref ref-type="bibr" rid="pcbi.1003016-Hartwell1">[10]</xref>, SL has been utilized as a therapeutic approach in cancer treatment employing a combination of genetic ablation (loss of tumor suppressor) and chemical inhibition. The first paradigm was set in BRCA1/2-deficient tumor cells, which are synthetic-lethal with inhibition of PolyADP-Ribose Polymerase (PARP) <xref ref-type="bibr" rid="pcbi.1003016-Farmer1">[11]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Helleday1">[13]</xref>. Small molecule PARP inhibitors are currently being evaluated in clinical trials in BRCA1- and BRCA2-deficient cancers (<italic>e.g.</italic> <xref ref-type="bibr" rid="pcbi.1003016-Fong1">[14]</xref>).</p>
      <p>The canonical interpretation of SL stipulates two mutually compensatory, parallel pathways capable of performing the same essential function <xref ref-type="bibr" rid="pcbi.1003016-Collins1">[2]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Tong1">[4]</xref>. Thus, disrupting a single pathway is viable, while disrupting both pathways is lethal. This concept of between-pathway synthetic lethality (bpSL) (<xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1A</xref>) led to the creation of computational approaches aiming at reconstructing interaction networks from pair-wise gene deletions or siRNA-induced gene knock-down screens in yeast and mammals <xref ref-type="bibr" rid="pcbi.1003016-Mizuarai1">[15]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Kelley1">[17]</xref>. However, recent genome-wide genetic interaction data revealed multiple negative interactions between mutations affecting the same molecular pathway or complex <xref ref-type="bibr" rid="pcbi.1003016-Bandyopadhyay1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Costanzo1">[5]</xref>,<xref ref-type="bibr" rid="pcbi.1003016-Baryshnikova1">[16]</xref>,<xref ref-type="bibr" rid="pcbi.1003016-Michaut1">[18]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Sopko1">[21]</xref>. For example, it was estimated that ∼9% <xref ref-type="bibr" rid="pcbi.1003016-Bellay1">[19]</xref> and in another study 14% <xref ref-type="bibr" rid="pcbi.1003016-Kelley1">[17]</xref> of all negative genetic interaction clusters belong to the same biological pathway. Several mechanistic models were suggested to explain within-pathway SL (wpSL) <xref ref-type="bibr" rid="pcbi.1003016-Boone1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Baryshnikova1">[16]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Costanzo2">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Bandyopadhyay2">[22]</xref>. The deletion of a gene might lead only to a partial degradation of an essential pathway which might be tolerable, whereas the double mutation leads to complete pathway degradation and lethality (<xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1B1</xref>). This is especially relevant for the interpretation of siRNA-based screens where the efficiency of a particular gene knock down is uncertain. A second possible mechanism suggests that steps in an essential pathway are internally redundant (<xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1B2</xref>). Lastly, two mutations may cumulatively degrade an essential protein complex, whereas they are individually viable (<xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1B3</xref>). This mechanism is consistent with the observations that molecular complexes are frequently characterized by the dominance of negative over positive genetic interactions between their components <xref ref-type="bibr" rid="pcbi.1003016-Michaut1">[18]</xref>. wpSL interactions between defects in components of a single protein complex are highly enriched for complexes with an essential component <xref ref-type="bibr" rid="pcbi.1003016-Baryshnikova1">[16]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Bandyopadhyay2">[22]</xref>. It was estimated that the contribution from within-complex interactions to the total number of within-pathway negative interactions does not exceed 7% <xref ref-type="bibr" rid="pcbi.1003016-Bellay1">[19]</xref>. Common to these mechanistic explanations of wpSL is that they involve either an essential pathway or an essential protein complex.</p>
      <fig id="pcbi-1003016-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003016.g001</object-id><label>Figure 1</label>
         <caption>
            <title>Schematic representation of mechanisms of (A) between-pathways Synthetic Lethality, (B) within-pathway Synthetic Lethality, and (C) within-reversible-pathway Synthetic Lethality.</title>
            <p>S: substrate, I: intermediate, P: product, C1–4: components of a protein complex. Red crosses define single mutations. For details see text.</p>
         </caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003016.g001" position="float" xlink:type="simple"/></fig>
      <p>Here, we highlight a novel scenario of wpSL involving two components of a non-essential pathway. The view of molecular pathways as unidirectional, linear reaction cascades is too simplistic. Pathway steps can be reversible which leads to forward and backward propagation of molecular events along the pathway increasing robustness and fidelity of the overall process <xref ref-type="bibr" rid="pcbi.1003016-Heyer1">[23]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Kitano1">[28]</xref>. Affecting both forward and reverse steps of the pathway by abrogating the corresponding enzymes creates scenarios in which the pathway flow can be trapped in an intermediate state that may be toxic to the cell or deprive the cell of a limiting resource (<xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1C</xref>). This can create a genetic scenario we define as within-reversible-pathway synthetic lethality (wrpSL), which is the subject of this study.</p>
      <p>Here, we study bpSL and wrpSL scenarios using mathematical modeling to better understand the system properties of these genetic relationships. We present a simplified model of the pathway applicable for its formal analytical study and performed <italic>in silico</italic> simulations for bpSL and wrpSL as well as synthetic dosage effects. Our main experimentally confirmed examples of wrpSL are in the homologous recombination DNA repair pathway. Homologous recombination (HR) is an important mechanism to maintain genome integrity <xref ref-type="bibr" rid="pcbi.1003016-Li1">[29]</xref> (Section S1 and Figure S1 in  for more discussion). Analysis of yeast gene interaction and pathway data suggests broad applicability of this novel concept.</p>
   </sec>
   <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
         <title>Homologous recombination and other DNA repair pathways are a hotspot for negative genetic interactions</title>
         <p>In order to assess the importance of within-pathway negative interactions we ranked all pathways from the KEGG database <xref ref-type="bibr" rid="pcbi.1003016-Kanehisa1">[30]</xref> according to their normalized proportion of negative interactions <xref ref-type="bibr" rid="pcbi.1003016-Costanzo1">[5]</xref> within each KEGG pathway (<xref ref-type="fig" rid="pcbi-1003016-g002">Figure 2</xref>). This analysis confirms the previous conclusion <xref ref-type="bibr" rid="pcbi.1003016-Bellay1">[19]</xref> that only a minority of within-pathway negative interactions can be explained by negative interactions within a complex (<xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1B3</xref>). In our analysis only 12% of all negative interactions were of this type (compared to 7% in <xref ref-type="bibr" rid="pcbi.1003016-Bellay1">[19]</xref>). Interestingly, HR ranks at the top with 27 within-pathway negative interactions between 20 KEGG pathway components (<xref ref-type="fig" rid="pcbi-1003016-g002">Figure 2</xref>), of which only a single one affects components of the same protein complex.</p>
         <fig id="pcbi-1003016-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003016.g002</object-id><label>Figure 2</label>
            <caption>
               <title>Normalized proportion of negative genetic interactions within one KEGG pathway.</title>
               <p>The proportion is related to the number of all possible pairwise interactions <italic>S</italic>(<italic>S</italic>−1)/2, where <italic>S</italic> is the size of the KEGG pathway. Negative interactions between components of a molecular complex were excluded (compare the fourth and the fifth columns). We counted the normalized number of negative genetic interactions within one pathway using recent data on the genome-wide screening of genetic interactions in yeast from <xref ref-type="bibr" rid="pcbi.1003016-Costanzo1">[5]</xref>, using the most stringent filter on the epistasis measure ε. Definitions of yeast signaling and metabolic pathways were taken from KEGG database <xref ref-type="bibr" rid="pcbi.1003016-Kanehisa1">[30]</xref>. Only KEGG pathways with a normalized proportion of ≥1% are shown. DNA repair KEGG pathways are highlighted in bold.</p>
            </caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003016.g002" position="float" xlink:type="simple"/></fig>
      </sec>
      <sec id="s2b">
         <title>Reversibility of the pathway steps in homologous recombination pathway</title>
         <p>Recent studies show that individual reaction steps in HR are reversible <xref ref-type="bibr" rid="pcbi.1003016-Heyer1">[23]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Symington1">[25]</xref> (Figure S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). The Rad51-ssDNA filament is a key intermediate in HR, as it performs the signature reactions of homology search and DNA strand invasion. The formation of this filament is catalyzed by specific co-factors (see Section S1 and Figure S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). The helicase Srs2 specifically targets the Rad51-ssDNA filament for disruption to reverse filament formation <xref ref-type="bibr" rid="pcbi.1003016-Veaute1">[31]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Krejci1">[32]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Liu1">[33]</xref>. The reversibility of the Rad51-ssDNA filament sets a new paradigm and draws attention to additional reversible steps and their mechanisms in HR, other DNA repair processes, and unrelated molecular pathways.</p>
      </sec>
      <sec id="s2c">
         <title>Simplest abstract toy model of DNA repair pathway with reversible steps and a toxic intermediate</title>
         <p>We derived the simplest linear mathematical model of a main DNA repair pathway with reversible steps and a toxic intermediate, and a compensatory pathway, which can recapitulate bpSL and wrpSL (<xref ref-type="fig" rid="pcbi-1003016-g003">Figure 3</xref>). Each state transition is catalyzed by an abstract enzyme, which may correspond to several biological entities (compare Figure S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref> with <xref ref-type="fig" rid="pcbi-1003016-g003">Figure 3</xref>). In wrpSL trapping of toxic intermediate I is caused by defects in the first backward reaction (I→S, R1, <italic>k</italic><sub>−1</sub>) and the second forward reaction (I→P, F2, <italic>k</italic><sub>2</sub>). The reversibility of the second step (reaction P→I, R1) is not essential for wrpSL to occur, but might be important for quantitative pathway characteristics. <xref ref-type="sec" rid="s1">Introduction</xref> of a final irreversible step (Figure S2 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>) would result in a kinetic proofreading mechanism <xref ref-type="bibr" rid="pcbi.1003016-Hopfield1">[34]</xref> (see Figures S2, S3 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref> and discussion there). Such a mechanism increases the robustness of DNA repair, as it avoids a futile P↔I cycle. However, in this simplest model we eliminated the final irreversible step to allow us analyzing the most essential features of wrpSL (Section S2 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). <xref ref-type="fig" rid="pcbi-1003016-g004">Figure 4</xref> explores conditions for various cellular fates (Normal Robust, <bold><italic>NR</italic></bold>: no single knockout leads to lethality (Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>); Normal Fragile, <bold><italic>NF</italic></bold>: single knockout can lead to lethality (Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>); Compensated, <bold><italic>C</italic></bold>: repair is performed by compensatory pathway; death due to DNA Damage, <bold><italic>DD</italic></bold>: steady state probability of DNA damage &gt;50%; and Death due to Toxic intermediates, <bold><italic>DT</italic></bold>: steady state probability of toxic intermediate &gt;50%). <xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> visualizes parametric conditions (see Section S2B in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref> for discussion).</p>
         <fig id="pcbi-1003016-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003016.g003</object-id><label>Figure 3</label>
            <caption>
               <title>Abstract representation of the recombinational DNA repair pathway.</title>
               <p>The scheme represents a simplified version of the pathway depicted in Figure S1 in Text S1 using the same abbreviations. Dynamic states <bold>S</bold>, <bold>I</bold>, <bold>P</bold> represent DNA damage substrate (<bold>S</bold>), toxic intermediate (<bold>I</bold>), and the product of repair (<bold>P</bold>). <bold>F1</bold> (<italic>e.g.</italic> Rad51), <bold>F2</bold> (<italic>e.g.</italic> Rad54), <bold>R1</bold> (<italic>e.g.</italic> Srs2), <bold>R2</bold> (<italic>e.g.</italic> Mph1) are enzymes in the main pathway, and <bold>F3-EC</bold> represent enzymes in the compensatory pathway. <italic>k</italic>s signify the kinetic rates of the model state transition steps. The two types of synthetic lethality (SL) are indicated: Red Xs – classic scenario of between-pathway SL (<italic>e.g. BRCA1</italic> or <italic>BRCA2</italic> mutant and PARP inhibition); Green Xs – within-reversible-pathway SL between two mutations in genes acting in a single non-essential pathway leading to the accumulation of a toxic intermediate (<italic>e.g. srs2 rad54</italic> double mutant). For more discussion see also Section S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>.</p>
            </caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003016.g003" position="float" xlink:type="simple"/></fig>
         <fig id="pcbi-1003016-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003016.g004</object-id><label>Figure 4</label>
            <caption>
               <title>Pathway steady states for various combinations of parameters in the mathematical model of DNA repair with reversible steps and a toxic intermediate.</title>
               <p>The classification of pathway steady states depends on the values of three control parameters, representing the ratios of some kinetic rates of the model (for more details see Section S2A in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>):  <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003016.e001" xlink:type="simple"/></inline-formula> The diagrams visualize the values of the control parameters where thickness of the solid arrows shows the relative value of the corresponding kinetic rate and the dashed arrows represent kinetic rates which values are irrelevant for a given scenario. Color coding shows partial orderings of the parameters important for a given pathway state (thickness of edges of the same color should be compared but not between color.</p>
            </caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003016.g004" position="float" xlink:type="simple"/></fig>
         <fig id="pcbi-1003016-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003016.g005</object-id><label>Figure 5</label>
            <caption>
               <title>Visualization of the steady states for the toy model in dependence of various parameters.</title>
               <p>The phase diagrams (<italic>r</italic><sub>2</sub>×<italic>r</italic><sub>1</sub> plane) show the qualitative behavior for small, intermediate and large values of the model parameters. Red color corresponds to the state for which <italic>P<sup>s</sup></italic>&gt;0.5 (DNA is repaired with probability &gt;50%). If <italic>P<sup>s</sup></italic>&lt;0.5 then the color is chosen as green if the probability of trapping in the intermediate state (<italic>I</italic>) is bigger than the propability of the initial unrepaired state (<italic>S</italic>), and as blue in the opposite case. The case <italic>k</italic><sub>1</sub> = 0 (F1↓) is represented separately on the right. In this case, another parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003016.e002" xlink:type="simple"/></inline-formula> is used instead of <italic>r</italic><sub>1</sub> for the phase plane. The case <italic>k−</italic><sub>1</sub> = 0 (R1↓) is treated separately on the top and only the <italic>r</italic><sub>2</sub> value is varied. The 14 model simulations listed in <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref> are shown by the circled numbers in the position of the chosen parameters.</p>
            </caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003016.g005" position="float" xlink:type="simple"/></fig>
      </sec>
      <sec id="s2d">
         <title>Examples of numerical simulations of the toy model</title>
         <p>Using analytical study and numerical simulations with some characteristic choices of kinetic rate values, we explored the dynamical behaviors of the simplest model (see <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>). Here, we discuss the qualitative results and interpretations, while the more formal derivation of these statements is found in Section S3 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>. To illustrate the static and dynamic properties of the toy model, we selected two typical positions (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> #1, #2) corresponding to <bold><italic>NR</italic></bold> and <bold><italic>NF</italic></bold> pathway states, respectively. From these “normal” conditions we simulated a number of single and double mutant/overexpression conditions as shown in <xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> (see also Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>).</p>
         <fig id="pcbi-1003016-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003016.g006</object-id><label>Figure 6</label>
            <caption>
               <title>Modeling possible scenarios of single and double synthetic lethal mutations.</title>
               <p>Pathway steady states depicted as <bold>Normal states</bold> (<bold>N</bold>) as Normal Robust (<bold>NR</bold>) and Normal Fragile (<bold>NF</bold>); <bold>Mutant states</bold> (<bold>M</bold>) as compensated state dependent on compensatory pathway EC(<bold>C</bold>); death from DNA damage (<bold>DD</bold>) and death from toxicity (<bold>DT</bold>). <bold>Dynamic plots</bold> show prediction of model for evolution of substrate (<bold>S</bold>), intermediate (<bold>I</bold>) and product (<bold>P</bold>) amounts over time corresponding to the choice of kinetic parameters shown on the <bold>Model diagram</bold>. (<bold>X-axis</bold>)-time, (<bold>Y-axis</bold>)-substances level. <bold>F1</bold>, <bold>F2</bold>, <bold>R1</bold>, <bold>R2</bold>, and <bold>EC</bold> refer to the enzymes catalyzing the two forward and two backward reactions as well as the compensatory pathway, respectively (see <xref ref-type="fig" rid="pcbi-1003016-g003">Figure 3</xref>). (↓)-complete knock-down or mutational loss of function; (↑)-over-expression. A deletion mutant was simulated by setting the corresponding kinetic rate constant to zero. An overexpression mutant was simulated by setting the corresponding kinetic rate constant sufficiently high to have a qualitative effect onto the steady state or the dynamics in the simulations. Some double mutants are not shown due to their triviality (such as F1↓F2↓) or difficulties with interpretation (such as F1↓R1↓). For more modeling scenarios see Figure S5 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>.</p>
            </caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003016.g006" position="float" xlink:type="simple"/></fig>
         <sec id="s2d1">
            <title>Normal pathway vs. irreversible pathway: reversibility does not affect efficiency, but is essential for pathway robustness</title>
            <p>We assume that in the <bold><italic>NR</italic></bold> and <bold><italic>NF</italic></bold> states under normal conditions forward steps of the pathways are faster than the backward steps. In this case the presence of reversible steps does not significantly affect the numerical solutions of the model equations, <italic>i.e.</italic> the efficiency of DNA repair (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> cases 1–3; <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, rows 1–3; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). However, the presence of reversible steps is important from the robustness point of view (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> cases 3, 7; <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, rows 3, 7; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). The gain in robustness through backward reactions is also illustrated by the fact that the difference between the <bold><italic>NR</italic></bold> and <bold><italic>NF</italic></bold> states is entirely defined by the ratio of the two backward reactions (<italic>r<sub>b</sub></italic>). The model recapitulates the fact that single enzyme deficiencies are not capable to completely block the overall DNA repair network. The F2 knock-out in <bold><italic>NF</italic></bold> is the only exception. When the first backward reaction is relatively slow <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003016.e003" xlink:type="simple"/></inline-formula>, the compensatory pathway cannot rescue the lethal phenotype (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 8; <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 8; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). This underlines the importance of efficient backward reactions.</p>
            <fig id="pcbi-1003016-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003016.g007</object-id><label>Figure 7</label>
               <caption>
                  <title>Modeling possible scenarios of single and double synthetic lethal mutations (continued).</title>
                  <p>Pathway steady states depicted as <bold>Normal states</bold> (<bold>N</bold>) as Normal Robust (<bold>NR</bold>) and Normal Fragile (<bold>NF</bold>); <bold>Mutant states</bold> (<bold>M</bold>) as compensated state dependent on compensatory pathway EC(<bold>C</bold>); death from DNA damage (<bold>DD</bold>) and death from toxicity (<bold>DT</bold>). <bold>Dynamic plots</bold> show prediction of model for evolution of substrate (<bold>S</bold>), intermediate (<bold>I</bold>) and product (<bold>P</bold>) amounts over time corresponding to the choice of kinetic parameters shown on the <bold>Model diagram</bold>. (<bold>X-axis</bold>)-time, (<bold>Y-axis</bold>)-substances level. <bold>F1</bold>, <bold>F2</bold>, <bold>R1</bold>, <bold>R2</bold>, and <bold>EC</bold> refer to the enzymes catalyzing the two forward and two backward reactions as well as the compensatory pathway, respectively (see <xref ref-type="fig" rid="pcbi-1003016-g003">Figure 3</xref>). (↓)-complete knock-down or mutational loss of function; (↑)-over-expression. A deletion mutant was simulated by setting the corresponding kinetic rate constant to zero. An overexpression mutant was simulated by setting the corresponding kinetic rate constant sufficiently high to have a qualitative effect onto the steady state or the dynamics in the simulations. Some double mutants are not shown due to their triviality (such as F1↓F2↓) or difficulties with interpretation (such as F1↓R1↓). For more modeling scenarios see Figure S5 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>.</p>
               </caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003016.g007" position="float" xlink:type="simple"/></fig>
         </sec>
         <sec id="s2d2">
            <title>Between-pathway Synthetic Lethality (bpSL): Disruption of main and compensatory pathways</title>
            <p>The model recapitulates canonical bpSL by putting two kinetic rates to zero simultaneously: <italic>k</italic><sub>1</sub> = <italic>k</italic><sub>3</sub> = 0 which causes cell death from accumulation of DNA damage (<bold><italic>DD</italic></bold>) (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 4; <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 4; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). Alternatively, in the case of <italic>k</italic><sub>2</sub> = <italic>k</italic><sub>3</sub> = 0 the pathway state will be <bold><italic>DT</italic></bold>, resulting in cell death from accumulation of toxic intermediates.</p>
         </sec>
         <sec id="s2d3">
            <title>Within-reversible-pathway Synthetic Lethality (wrpSL): Trapping a toxic intermediate</title>
            <p>The wrpSL case is modeled by putting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003016.e004" xlink:type="simple"/></inline-formula>. As it can be seen (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 5; <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 5; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>), this creates a kinetic trap in the toxic intermediate state <italic>I</italic> (<bold><italic>DT</italic></bold>). The model recapitulates the situation observed in the <italic>srs2 rad54</italic> double mutant <xref ref-type="bibr" rid="pcbi.1003016-Heyer1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Palladino1">[35]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Heyer2">[36]</xref>. Modeling predicts that mammalian cells deficient in RAD54 or its close paralog RAD54B should also be sensitive to inhibition of enzymes, such as FBH1, FANCJ, or RECQ5 <xref ref-type="bibr" rid="pcbi.1003016-Fugger1">[37]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Schwendener1">[39]</xref> (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> cases 5, 8; <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 5; <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 8; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>), that are postulated or shown to dissociate the RAD51-ssDNA filament (Figures S1, S2 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>).</p>
         </sec>
         <sec id="s2d4">
            <title>Aspects of reversibility</title>
            <p>Blocking the pathway upstream by eliminating the F1 reaction in the normal pathway states (<bold><italic>NR</italic></bold> and <bold><italic>NF</italic></bold>) does not lead to cell death. However, this affects the kinetics of the process, because repair is carried out by the compensatory pathway (state C), which is slower than the principal one (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 6; <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 6; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). Therefore, the time of repair increases and the cell fate depends on the efficiency of the compensatory pathway, which might be cell type-specific. The situation may result in cell death if the kinetics of the process are too slow or the efficiency of DNA damage repair by the compensatory pathway is below an essential threshold. This scenario may represent cancer cells with certain DNA repair defects, which can be compensated by alternative pathways. In such cases, therapeutic targeting of the compensatory pathways may result in fast accumulation of DNA damage, selectively killing the cancer cells, representing the classic bpSL concept.</p>
            <p>When the pathway is blocked downstream at F2 (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 7; <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 7; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>) the time of repair significantly increases, as the pathway is only partially compensated. This scenario can be rescued by reducing <italic>k</italic><sub>1</sub> or increasing <italic>k</italic><sub>−1</sub> (state <bold>C</bold>). The scenario recapitulates RAD54-deficient cells, where sub-lethal levels of toxic intermediates and unrepaired DNA increase genetic instability <xref ref-type="bibr" rid="pcbi.1003016-Heyer2">[36]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-McManus1">[40]</xref>. This last scenario of a downstream block (F2 knockout: <xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 7; <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 7; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>) can be rescued by overexpression of R1 (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 9; <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 9; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). The modeling predicts that this will accelerate the backward reactions, favor the compensatory route and increase repair of damaged DNA by the compensatory pathway (state <bold>C</bold>). The modeling also highlights the benefit of reversibility. In <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref> (row 8), a decrease in reversibility (10-fold reduction in R1) leads to significantly less repaired product in mutants that block the downstream step (F2). Complete inhibition of the R1 step leads to wrpSL in cells lacking F2, such as RAD54B-deficient cells (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 8; <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 8; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>, see above). The modeling suggests that cells deficient in the downstream forward reaction (F2, <italic>e.g.</italic> RAD54B<sup>−/−</sup>) are potentially under selective pressure to strengthen the upstream backward reaction (R1, <italic>e.g.</italic> overexpression of FBH1, FANCJ, or RECQ5).</p>
         </sec>
         <sec id="s2d5">
            <title>Activating mutations or overexpression can create within-reversible-pathway-synthetic dosage lethality</title>
            <p>The computational model allows making predictions in less intuitive cases of model perturbations. The lethal phenotype by R2 overexpression (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 10; <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 10; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>) can be partially rescued by eliminating F1 (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 12; <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 12; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>), as repair is carried out by the compensatory pathway (state <bold>C</bold>). The modeling illustrates how a defect in an early HR gene such as <italic>RAD51</italic>, <italic>BRCA2</italic>, <italic>RAD52</italic>, or the <italic>RAD51</italic> paralogs would provide a selective advantage in cells overexpressing enzymes of the R2 backward reaction (yeast Mph1, human RTEL1 or FANCM).</p>
            <p>F1 overexpression amplifies the effect of an F2 mutation, creating synthetic-lethal dosage and leading to wrpSL due to the accumulation of toxic intermediates (state <bold><italic>DT</italic></bold>) (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 13; <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 13; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). This suggests that inhibition of F2 (for example RAD54/RAD54B) would be particularly effective to sensitize cancer cells overexpressing F1 components (<italic>e.g.</italic> RAD51 paralogs, RAD51, RAD52, BRAC2 <xref ref-type="bibr" rid="pcbi.1003016-Klein1">[41]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Christodoulopoulos1">[45]</xref>), a non-intuitive insight derived from the mathematical modeling.</p>
            <p>Blocking the compensatory pathway and overexpressing R2 also creates synthetic lethal dosage interaction, causing accumulation of toxic intermediates due to the increase in backward reactions kinetics (state <bold><italic>DT</italic></bold>) (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 14; <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 14; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). However, if the final irreversible step of DNA repair will be taken into consideration (P→I2a/b→EP, <xref ref-type="fig" rid="pcbi-1003016-g003">Figure 3</xref>), slow conversion of all favorable DNA configurations from the futile I↔P cycle into the completely repaired DNA state will rescue cells (similar to scenario depicted in <xref ref-type="fig" rid="pcbi-1003016-g007">Figure 7</xref>, row 10). This example is interesting, because it demonstrates that interference with compensatory pathways by drugs might have a therapeutic importance if the backward steps of the main pathway are considered. Finally, the computational model predicts that a similar trap in the intermediate state can be created by eliminating R1 and overexpressing R2 (<xref ref-type="fig" rid="pcbi-1003016-g005">Figure 5</xref> case 3; Figure S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>; Figure S5, row 3 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>).</p>
         </sec>
      </sec>
   </sec>
   <sec id="s3">
      <title>Discussion</title>
      <p>Synthetic lethality/sickness and synthetic dosage lethality are important genetic tools to assign individual gene functions into molecular pathways <xref ref-type="bibr" rid="pcbi.1003016-Collins1">[2]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Tong1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Kroll1">[7]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Iorns1">[9]</xref>. The canonical interpretation for two mutants found to be synthetically lethal or sick stipulates that the encoded gene products function in different parallel pathways that can mutually compensate (bpSL) <xref ref-type="bibr" rid="pcbi.1003016-Collins1">[2]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Tong1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Kroll1">[7]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Iorns1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Mizuarai1">[15]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Kelley1">[17]</xref>. However, computational analysis of genetic interaction data combined with protein interaction data revealed multiple negative interactions between mutations affecting functions in the same molecular pathway or complex (wpSL) <xref ref-type="bibr" rid="pcbi.1003016-Bandyopadhyay1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Costanzo1">[5]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Baryshnikova1">[16]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Michaut1">[18]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Sopko1">[21]</xref>. Several mechanisms of wpSL have been proposed (<xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1B</xref>), and they all involve either essential pathways or essential protein complexes. In extension of this fundamental concept of wpSL, there are several cases of SL between mutants encoding proteins acting in HR, a pathway that is not essential in yeast <xref ref-type="bibr" rid="pcbi.1003016-Palladino1">[35]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Fabre1">[46]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Maftahi1">[48]</xref>. We term this novel genetic interaction within-reversible-pathway Synthetic Lethality (wrpSL; <xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1C</xref>) and provide a novel mechanistic explanation for wpSL, which can create SL within a non-essential pathway or between hypomorphic mutations in an essential pathway that is different from a model invoking sequential pathway degradation by accumulation of partial defects of successive steps (<xref ref-type="fig" rid="pcbi-1003016-g001">Figure 1B1</xref>).</p>
      <p>Here, we explore by mathematical modeling the system properties of wrpSL. The modeling must make assumptions about the system properties (state transition rates, relative pathway efficiencies, <italic>etc.</italic>) and identifies several conditions to be met for wrpSL. 1) Reversibility of pathway steps. In fact, only the first pathway step must be reversible, whereas reversibility of the second pathway steps enables additional genetic scenarios. 2) Possibility of kinetic trapping of an intermediate state of the pathway when both the backward and forward reactions are compromised. The trapping <italic>per se</italic> can be detrimental due to blockage of cell signaling, sequestering an essential compound, or toxicity. We have assumed lethal toxicity in our model. 3) The possibility of rescue by a parallel compensatory pathway may not be strictly required, but highlights the applicability of this concept to non-essential pathways.</p>
      <p>The mathematical model is validated by the experimentally observed recombination-dependent SL of the <italic>srs2 rad54</italic> double mutant in budding yeast <xref ref-type="bibr" rid="pcbi.1003016-Palladino1">[35]</xref> (<xref ref-type="fig" rid="pcbi-1003016-g003">Figure 3</xref>, Figure S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>, <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 5). Srs2-defective cells are unable to reverse Rad51-ssDNA filaments. These Rad51-ssDNA filaments represent toxic intermediates that accumulate in the cell due to kinetic trapping and interfere with cell viability. The key functions of the Rad54 protein are to assist in DNA strand invasion and allowing DNA synthesis off the invading 3′-end <xref ref-type="bibr" rid="pcbi.1003016-Heyer2">[36]</xref>. Hence, in the <italic>srs2 rad54</italic> double mutant Rad51-ssDNA filaments and/or D-loops may accumulate forming a toxic intermediate that leads to cell death (Figure S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>; <xref ref-type="fig" rid="pcbi-1003016-g003">Figure 3</xref> green pair and <xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 5). This interpretation is supported by the observation that lethality in this double mutant is suppressed by a defect in Rad51-ssDNA filament formation (mutations in <italic>RAD51</italic>, <italic>RAD55</italic>, <italic>RAD57</italic>, or <italic>RAD52</italic>) <xref ref-type="bibr" rid="pcbi.1003016-Schild1">[49]</xref> (see Figure S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>), what has been termed recombination-dependent lethality. Preventing Rad51-ssDNA filament formation allows bypass of recombination by alternative means of DNA repair (for DSBs: Nonhomologous endjoining or single-strand annealing; for gaps: Translesion synthesis or fork regression <xref ref-type="bibr" rid="pcbi.1003016-Heyer1">[23]</xref>; see Figure S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>). The recombination-dependent lethality of <italic>srs2 rad54</italic> is not unique and is also found in additional double mutants in recombinational repair genes including the double mutants <italic>mph1 mus81</italic>, <italic>mph1 mms4</italic>, <italic>srs2 sgs1 and sgs1</italic> (or <italic>top3</italic> or <italic>rmi1</italic>) and <italic>mus81</italic> (or <italic>mms4</italic>) which likely reflect additional examples of wrpSL possibly involving different toxic intermediates <xref ref-type="bibr" rid="pcbi.1003016-Palladino1">[35]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Fabre1">[46]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-StOnge1">[53]</xref>. As discussed in detail in Section S1 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>, the synthetic lethalities involving <italic>sgs1</italic> are more complex, because of the multiple roles of Sgs1-Top3-Rmi1 in HR, and could be caused also by other mechanisms of SL.</p>
      <p>Further modeling revealed additional genetic conditions including overexpression of specific pathway enzymes that are predicted to lead to wrpSL (<xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>). The mathematical modeling also reveals the importance of reversible pathway steps, which are validated by genetic and biochemical experiments in yeast <xref ref-type="bibr" rid="pcbi.1003016-Heyer1">[23]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Symington1">[25]</xref>. First, the existence of reversible pathway steps does not affect normal pathway progression (<xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, rows 1–3). Second, reversible pathway steps allow much more efficient and timely use of compensatory pathways (<xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 6). Third, reversible pathways coupled with compensatory pathways avoid lethality of single mutations (<xref ref-type="fig" rid="pcbi-1003016-g006">Figure 6</xref>, row 7). The existence of reversible intermediates in HR, and possibly other molecular pathways, has been proposed to increase the robustness of the overall DNA repair system <xref ref-type="bibr" rid="pcbi.1003016-Heyer1">[23]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Symington1">[25]</xref>, and here we provide quantitative modeling evidence and formal analysis of this assertion.</p>
      <p>An important question is how general wrpSL might be or whether it is an idiosyncrasy of the recombinational repair pathway. Even if wrpSL were restricted to HR, this concept provides significant potential application in anti-cancer therapy. However, there is considerable evidence that many molecular pathways include reversible steps catalyzed by different enzymes in the forward and backward directions (see <xref ref-type="fig" rid="pcbi-1003016-g008">Figure 8</xref>). Any of those processes can be theoretically trapped into one of their intermediate states if two regulators of forward and backward steps are inactive. In these cases, the accumulating intermediate might be toxic, block proper signal propagation or prevent resource recycling. Focusing on three examples of reversible protein modifications (phosphorylation by Cdc5/dephosphorylation by Cdc14, sumoylation by Slx5–Slx8/desumoylation by Ulp1, Nup60, ubiquitylation by Rad6–Rad18/deubiquitylation by Bre5, Ubp3 or degradation dependent on Doa1, Rpn6; see Figure S6 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref> for details), we found ample evidence in published genetic interaction data that are consistent with the wrpSL mechanism. These examples have not been fully explored, but are consistent with the wrpSL concept and amenable to test specific predictions.</p>
      <fig id="pcbi-1003016-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003016.g008</object-id><label>Figure 8</label>
         <caption>
            <title>Examples of molecular processes with alternative pathways and potential to kinetic trap.</title>
            <p>A) Multiple post-translational protein modifications (phosphorylation followed by ubiquitination; acetylation followed by phosphorylation; sumotargeted ubiquitination, <italic>etc.</italic>). M1 and M2 represent two types of post-translational modifications. MOD1–4 represent enzymes catalyzing the reactions. Kinetic trapping of an intermediate modification can drastically disturb the balance between signaling pathways (<italic>e.g.</italic> #23 in <xref ref-type="fig" rid="pcbi-1003016-g002">Figure 2</xref>) B) Protein folding control by chaperones. Protein folding is controlled by chaperones (#18 in <xref ref-type="fig" rid="pcbi-1003016-g002">Figure 2</xref>) and may generate partially unfolded proteins as toxic intermediates which are subject to degradation <xref ref-type="bibr" rid="pcbi.1003016-Hartl1">[55]</xref>. Regulation of protein folding homeostasis is essential for protein pool control <xref ref-type="bibr" rid="pcbi.1003016-Voisine1">[56]</xref>; C) Lack of balance between production and detoxification of ROS leads to significant increases or drop in ROS levels that can be detrimental for cell signaling <xref ref-type="bibr" rid="pcbi.1003016-Bartz1">[57]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Karihtala1">[59]</xref> (#19 in <xref ref-type="fig" rid="pcbi-1003016-g002">Figure 2</xref>). D) Coordinated sumoylation-desumoylation is important for proper signal propagation <xref ref-type="bibr" rid="pcbi.1003016-Gareau1">[60]</xref>–<xref ref-type="bibr" rid="pcbi.1003016-Wilkinson1">[62]</xref>. E) Glycan biosynthesis and protein glycosylation depend on the availability of common carrier dolichol phosphate (P-DOL). Correct recycling of P-DOL is important for sustaining the pool and utilization of this carrier in other glycans biosynthesis pathways. Kinetic trapping can consume the pool of P-DOL and perturb cell signaling <xref ref-type="bibr" rid="pcbi.1003016-Moremen1">[63]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Schwarz1">[64]</xref> (#2, 3 and 26 in <xref ref-type="fig" rid="pcbi-1003016-g002">Figure 2</xref>) F) Protein ubiquitylation is not only a tagging signal for degradation, but also involved in signaling. The correct tuning between two functions of ubiquitylation depends on the type and the length of ubiquitin (UB) polymer transferred to the protein and at the ubiquitylation site <xref ref-type="bibr" rid="pcbi.1003016-Kulathu1">[65]</xref>. Monoubiquitylated proteins participate in signal transduction <xref ref-type="bibr" rid="pcbi.1003016-Sigismund1">[66]</xref>, <xref ref-type="bibr" rid="pcbi.1003016-Vertegaal1">[67]</xref>, whereas K48-polyubiquitylated proteins are redirected to the proteasome for proteolysis. Thus, the balance between protein homeostasis and ubiquitin-dependent signaling is essential <xref ref-type="bibr" rid="pcbi.1003016-Chen1">[68]</xref>.</p>
         </caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003016.g008" position="float" xlink:type="simple"/></fig>
      <p>In summary, genetic and biochemical data strongly support the significance of the wrpSL mechanism in HR, and existing data are consistent with the notion that wrpSL could be a general, widely applicable type of genetic interaction. This may refine our understanding of relationships between gene products and will help to improve pathway reconstruction. In particular, our mathematical modeling provides a conceptual framework for guiding systematic exploitation of mutations and changes in the expression profiles of HR genes and potentially genes of other pathways to induce SL.</p>
   </sec>
   <sec id="s4" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s4a">
         <title>Model formalism and model solution</title>
         <p>The simplest mathematical model of <xref ref-type="fig" rid="pcbi-1003016-g003">Figure 3</xref> was converted into a set of linear ordinary differential equations using the standard chemical kinetics formalism. The steady state model properties were analyzed analytically and exemplified with numerical simulations. Classification of the pathway states according to the extreme (large or small) values of the control parameters and the corresponding asymptotic solutions follow the methodology of the asymptotology of reaction networks <xref ref-type="bibr" rid="pcbi.1003016-Gorban1">[54]</xref>.</p>
      </sec>
      <sec id="s4b">
         <title>Numerical simulations</title>
         <p>All numerical simulations were performed using SBTOOLBOX package for Matlab (Section S4 in <xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref>).</p>
      </sec>
   </sec>
   <sec id="s5">
      <title>Supporting Information</title>
<supplementary-material id="pcbi.1003016.s001" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1003016.s001" position="float" xlink:type="simple">
<label>Text S1</label>
<caption><p><xref ref-type="supplementary-material" rid="pcbi.1003016.s001">Text S1</xref> contains Figure S1–S6, Section S1–S4, and Table S1.</p>
      <p>(PDF)</p>
</caption></supplementary-material>
   </sec>
</body>
<back>
   <ack>
      <p>We thank J. Hall, M.-H. Stern, T. Popova, L. Calzone, R. Janke, S. Ceballos, C. Fasching, S. Kowalczykowski, M.Lichten and M. Savageau for valuable comments on the manuscript. WDH thanks the Institut Curie and especially Dr. Alain Nicolas for the hospitality during his sabbatical stay.</p>
   </ack>
   <ref-list>
      <title>References</title>
      <ref id="pcbi.1003016-Dobzhansky1"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dobzhansky</surname><given-names>T</given-names></name> (<year>1946</year>) <article-title>Genetics of natural populations. XIII. Recombination and variability in populations of <italic>Drosophila pseudoobscura</italic></article-title>. <source>Genetics</source> <volume>31</volume>: <fpage>269</fpage>–<lpage>290</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Collins1"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Collins</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Maas</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Roguev</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fillingham</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map</article-title>. <source>Nature</source> <volume>446</volume>: <fpage>806</fpage>–<lpage>810</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Bandyopadhyay1"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bandyopadhyay</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mehta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kuo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sung</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Chuang</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Rewiring of Genetic Networks in Response to DNA Damage</article-title>. <source>Science</source> <volume>330</volume>: <fpage>1385</fpage>–<lpage>1389</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Tong1"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tong</surname><given-names>AHY</given-names></name>, <name name-style="western"><surname>Evangelista</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Parsons</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bader</surname><given-names>GD</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Systematic genetic analysis with ordered arrays of yeast deletion mutants</article-title>. <source>Science</source> <volume>294</volume>: <fpage>2363</fpage>–<lpage>2368</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Costanzo1"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Costanzo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Baryshnikova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bellay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Spear</surname><given-names>ED</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The genetic landscape of a cell</article-title>. <source>Science</source> <volume>327</volume>: <fpage>425</fpage>–<lpage>431</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Boone1"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boone</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bussey</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>BJ</given-names></name> (<year>2007</year>) <article-title>Exploring genetic interactions and networks with yeast</article-title>. <source>Nature Reviews Genetics</source> <volume>8</volume>: <fpage>437</fpage>–<lpage>449</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Kroll1"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kroll</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Hyland</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Hieter</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>JJ</given-names></name> (<year>1996</year>) <article-title>Establishing genetic interactions by a synthetic dosage lethality phenotype</article-title>. <source>Genetics</source> <volume>143</volume>: <fpage>95</fpage>–<lpage>102</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Silva1"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Silva</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Marran</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Parker</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Golding</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Profiling essential genes in human mammary cells by multiplex RNAi screening</article-title>. <source>Science</source> <volume>319</volume>: <fpage>617</fpage>–<lpage>620</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Iorns1"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iorns</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lord</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ashworth</surname><given-names>A</given-names></name> (<year>2007</year>) <article-title>Utilizing RNA interference to enhance cancer drug discovery</article-title>. <source>Nature Reviews Drug Discovery</source> <volume>6</volume>: <fpage>556</fpage>–<lpage>568</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Hartwell1"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hartwell</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Szankasi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Friend</surname><given-names>SH</given-names></name> (<year>1997</year>) <article-title>Integrating genetic approaches into the discovery of anticancer drugs</article-title>. <source>Science</source> <volume>278</volume>: <fpage>1064</fpage>–<lpage>1068</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Farmer1"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Farmer</surname><given-names>H</given-names></name>, <name name-style="western"><surname>McCabe</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Lord</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Tutt</surname><given-names>ANJ</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>DA</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source> <volume>434</volume>: <fpage>917</fpage>–<lpage>921</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Bryant1"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bryant</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Schultz</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Parker</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Flower</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title>. <source>Nature</source> <volume>434</volume>: <fpage>913</fpage>–<lpage>917</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Helleday1"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Helleday</surname><given-names>T</given-names></name> (<year>2011</year>) <article-title>The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings</article-title>. <source>Molecular Oncology</source> <volume>5</volume>: <fpage>387</fpage>–<lpage>393</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Fong1"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fong</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Boss</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Yap</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Tutt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</article-title>. <source>New England Journal of Medicine</source> <volume>361</volume>: <fpage>123</fpage>–<lpage>134</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Mizuarai1"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mizuarai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kotani</surname><given-names>H</given-names></name> (<year>2010</year>) <article-title>Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements</article-title>. <source>Human Genetics</source> <volume>128</volume>: <fpage>567</fpage>–<lpage>575</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Baryshnikova1"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baryshnikova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Costanzo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Koh</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Quantitative analysis of fitness and genetic interactions in yeast on a genome scale</article-title>. <source>Nature Methods</source> <volume>7</volume>: <fpage>1017</fpage>–<lpage>1024</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Kelley1"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kelley</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ideker</surname><given-names>T</given-names></name> (<year>2005</year>) <article-title>Systematic interpretation of genetic interactions using protein networks</article-title>. <source>Nature Biotechnology</source> <volume>23</volume>: <fpage>561</fpage>–<lpage>566</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Michaut1"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Michaut</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Baryshnikova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Costanzo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>BJ</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Protein complexes are central in the yeast genetic landscape</article-title>. <source>PLoS Comput Biol</source> <volume>7</volume>: <fpage>e1001092</fpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Bellay1"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bellay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Atluri</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sing</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Toufighi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Costanzo</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Putting genetic interactions in context through a global modular decomposition</article-title>. <source>Genome Research</source> <volume>21</volume>: <fpage>1375</fpage>–<lpage>1387</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Costanzo2"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Costanzo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Baryshnikova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Boone</surname><given-names>C</given-names></name> (<year>2011</year>) <article-title>Charting the genetic interaction map of a cell</article-title>. <source>Current Opinion in Biotechnology</source> <volume>22</volume>: <fpage>66</fpage>–<lpage>74</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Sopko1"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sopko</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Preston</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chua</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Papp</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Mapping pathways and phenotypes by systematic gene overexpression</article-title>. <source>Molecular Cell</source> <volume>21</volume>: <fpage>319</fpage>–<lpage>330</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Bandyopadhyay2"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bandyopadhyay</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kelley</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Krogan</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Ideker</surname><given-names>T</given-names></name> (<year>2008</year>) <article-title>Functional maps of protein complexes from quantitative genetic interaction data</article-title>. <source>PLoS Comput Biol</source> <volume>4</volume>: <fpage>e1000065</fpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Heyer1"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heyer</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Ehmsen</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>Regulation of homologous recombination in eukaryotes</article-title>. <source>Annual Reviews Genetics</source> <volume>44</volume>: <fpage>113</fpage>–<lpage>139</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Kanaar1"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kanaar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wyman</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rothstein</surname><given-names>R</given-names></name> (<year>2008</year>) <article-title>Quality control of DNA break metabolism: in the ‘end’, it's a good thing</article-title>. <source>EMBO Journal</source> <volume>27</volume>: <fpage>581</fpage>–<lpage>588</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Symington1"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Symington</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Heyer</surname><given-names>WD</given-names></name> (<year>2006</year>) <article-title>Some disassembly required: role of DNA translocases in the disruption of recombination intermediates and dead-end complexes</article-title>. <source>Genes and Development</source> <volume>20</volume>: <fpage>2479</fpage>–<lpage>2486</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Alon1"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alon</surname><given-names>U</given-names></name> (<year>2003</year>) <article-title>Biological Networks: The tinkerer as an engineer</article-title>. <source>Science</source> <volume>301</volume>: <fpage>1866</fpage>–<lpage>1867</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Savageau1"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Savageau</surname><given-names>M</given-names></name> (<year>1971</year>) <article-title>Parameter sensitivity as a criterion for evaluating and comparing the performance of biochemical systems</article-title>. <source>Nature</source> <volume>229</volume>: <fpage>542</fpage>–<lpage>544</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Kitano1"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kitano</surname><given-names>H</given-names></name> (<year>2004</year>) <article-title>Biological robustness</article-title>. <source>Nature Reviews Genetics</source> <volume>5</volume>: <fpage>826</fpage>–<lpage>837</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Li1"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Heyer</surname><given-names>WD</given-names></name> (<year>2008</year>) <article-title>Homologous recombination in DNA repair and DNA damage tolerance</article-title>. <source>Cell Research</source> <volume>18</volume>: <fpage>99</fpage>–<lpage>113</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Kanehisa1"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Goto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Furumichi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tanabe</surname><given-names>M</given-names></name> (<year>2012</year>) <article-title>KEGG for integration and interpretation of large-scale molecular data sets</article-title>. <source>Nucleic Acids Research</source> <volume>40</volume>: <fpage>D109</fpage>–<lpage>114</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Veaute1"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Veaute</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Jeusset</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Soustelle</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kowalczykowski</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Le Cam</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>The Srs2 helicase prevents recombination by disrupting Rad51 nucleoprotein filaments</article-title>. <source>Nature</source> <volume>423</volume>: <fpage>309</fpage>–<lpage>312</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Krejci1"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Krejci</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Van Komen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Villemain</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>MS</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>DNA helicase Srs2 disrupts the Rad51 presynaptic filament</article-title>. <source>Nature</source> <volume>423</volume>: <fpage>305</fpage>–<lpage>309</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Liu1"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Renault</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Veaute</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Fabre</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Stahlberg</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Rad51 paralogs Rad55-Rad57 balance the anti-recombinase function of Srs2 in Rad51 pre-synaptic filament formation</article-title>. <source>Nature</source> <volume>479</volume>: <fpage>245</fpage>–<lpage>248</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Hopfield1"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hopfield</surname><given-names>JJ</given-names></name> (<year>1974</year>) <article-title>Kintic proofreading: a new mechanism for reducing errors in biosynthetic processes requiting high specifcity</article-title>. <source>Proceedings National Academy of Sciences USA</source> <volume>71</volume>: <fpage>4135</fpage>–<lpage>4139</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Palladino1"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Palladino</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>HL</given-names></name> (<year>1992</year>) <article-title>Analysis of mitotic and meiotic defects in <italic>Saccharomyces cerevisiae</italic> SRS2 DNA helicase mutants</article-title>. <source>Genetics</source> <volume>132</volume>: <fpage>23</fpage>–<lpage>37</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Heyer2"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heyer</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Rolfsmeier</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>XP</given-names></name> (<year>2006</year>) <article-title>Rad54: the Swiss Army knife of homologous recombination?</article-title> <source>Nucleic Acids Research</source> <volume>34</volume>: <fpage>4115</fpage>–<lpage>4125</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Fugger1"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fugger</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mistrik</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Danielsen</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Dinant</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Falck</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Human Fbh1 helicase contributes to genome maintenance via pro- and anti-recombinase activities</article-title>. <source>Journal of Cell Biology</source> <volume>186</volume>: <fpage>655</fpage>–<lpage>663</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Sommers1"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sommers</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Rawtani</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bugreev</surname><given-names>DV</given-names></name>, <name name-style="western"><surname>Mazin</surname><given-names>AV</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>FANCJ uses its motor ATPase to destabilize protein-DNA complexes, unwind triplexes, and inhibit RAD51 strand exchange</article-title>. <source>Journal of Biological Chemistry</source> <volume>284</volume>: <fpage>7502</fpage>–<lpage>7514</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Schwendener1"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwendener</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Raynard</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Paliwal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kanagaraj</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Physical Interaction of RECQ5 Helicase with RAD51 Facilitates Its Anti-recombinase Activity</article-title>. <source>Journal of Biological Chemistry</source> <volume>285</volume>: <fpage>15739</fpage>–<lpage>15745</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-McManus1"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McManus</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Barrett</surname><given-names>IJ</given-names></name>, <name name-style="western"><surname>Nouhi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hieter</surname><given-names>P</given-names></name> (<year>2009</year>) <article-title>Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing</article-title>. <source>Proceedings National Academy of Sciences USA</source> <volume>106</volume>: <fpage>3276</fpage>–<lpage>3281</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Klein1"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Klein</surname><given-names>HL</given-names></name> (<year>2008</year>) <article-title>The consequences of Rad51 overexpression for normal and tumor cells</article-title>. <source>DNA Repair</source> <volume>7</volume>: <fpage>686</fpage>–<lpage>693</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Feng1"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Feng</surname><given-names>ZH</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Bussen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Rad52 inactivation is synthetically lethal with BRCA2 deficiency</article-title>. <source>Proceedings National Academy of Sciences USA</source> <volume>108</volume>: <fpage>686</fpage>–<lpage>691</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Slupianek1"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Slupianek</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schmutte</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tombline</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nieborowska-Skorska</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hoser</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance</article-title>. <source>Molecular Cell</source> <volume>8</volume>: <fpage>795</fpage>–<lpage>806</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Maacke1"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maacke</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Opitz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jost</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hamdorf</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Henning</surname><given-names>W</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer</article-title>. <source>International Journal of Cancer</source> <volume>88</volume>: <fpage>907</fpage>–<lpage>913</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Christodoulopoulos1"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Christodoulopoulos</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Malapetsa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schipper</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Golub</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Radding</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia</article-title>. <source>Clinical Cancer Research</source> <volume>5</volume>: <fpage>2178</fpage>–<lpage>2184</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Fabre1"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fabre</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Heyer</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Gangloff</surname><given-names>S</given-names></name> (<year>2002</year>) <article-title>Alternate pathways involving Sgs1/Top3, Mus81/Mms4, and Srs2 prevent formation of toxic recombination intermediates from single-stranded gaps created by DNA replication</article-title>. <source>Proceedings National Academy of Sciences USA</source> <volume>99</volume>: <fpage>16887</fpage>–<lpage>16892</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Gangloff1"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gangloff</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Soustelle</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fabre</surname><given-names>F</given-names></name> (<year>2000</year>) <article-title>Homologous recombination is responsible for cell death in the absence of the Sgs1 and Srs2 helicases</article-title>. <source>Nature Genetics</source> <volume>25</volume>: <fpage>192</fpage>–<lpage>194</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Maftahi1"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maftahi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hope</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Delgado-Cruzata</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Freyer</surname><given-names>GA</given-names></name> (<year>2002</year>) <article-title>The severe slow growth of Delta srs2 Delta rqh1 in Schizosaccharomyces pombe is suppressed by loss of recombination and checkpoint genes</article-title>. <source>Nucleic Acids Research</source> <volume>30</volume>: <fpage>4781</fpage>–<lpage>4792</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Schild1"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schild</surname><given-names>D</given-names></name> (<year>1995</year>) <article-title>Suppression of a new allele of the yeast <italic>RAD52</italic> gene by overexpression of <italic>RAD51</italic>, mutations in <italic>srs2</italic> and <italic>ccr4</italic>, or mating-type heterozygosity</article-title>. <source>Genetics</source> <volume>140</volume>: <fpage>115</fpage>–<lpage>127</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Trowbridge1"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Trowbridge</surname><given-names>K</given-names></name>, <name name-style="western"><surname>McKim</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Brill</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Sekelsky</surname><given-names>J</given-names></name> (<year>2007</year>) <article-title>Synthetic lethality of <italic>Drosophila</italic> in the absence of the MUS81 endonuclease and the DmBlm helicase is associated with elevated apoptosis</article-title>. <source>Genetics</source> <volume>176</volume>: <fpage>1993</fpage>–<lpage>2001</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-DeMuyt1"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Muyt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jessop</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kolar</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sourirajan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>JH</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>BLM Helicase Ortholog Sgs1 Is a Central Regulator of Meiotic Recombination Intermediate Metabolism</article-title>. <source>Molecular Cell</source> <volume>46</volume>: <fpage>43</fpage>–<lpage>53</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Zakharyevich1"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zakharyevich</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>N</given-names></name> (<year>2012</year>) <article-title>Delineation of Joint Molecule Resolution Pathways in Meiosis Identifies a Crossover-Specific Resolvase</article-title>. <source>Cell</source> <volume>149</volume>: <fpage>334</fpage>–<lpage>347</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-StOnge1"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>St Onge</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Mani</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Oh</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Proctor</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fung</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions</article-title>. <source>Nature Genetics</source> <volume>39</volume>: <fpage>199</fpage>–<lpage>206</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Gorban1"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gorban</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Radulescu</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Zinovyev</surname><given-names>A</given-names></name> (<year>2010</year>) <article-title>Asymptotology of chemical reactions networks.</article-title>. <source>Chemical Engineering Sciences</source> <volume>65</volume>: <fpage>2310</fpage>–<lpage>2324</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Hartl1"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hartl</surname><given-names>FU</given-names></name>, <name name-style="western"><surname>Bracher</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hayer-Hartl</surname><given-names>M</given-names></name> (<year>2011</year>) <article-title>Molecular chaperones in protein folding and proteostasis</article-title>. <source>Nature</source> <volume>475</volume>: <fpage>324</fpage>–<lpage>332</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Voisine1"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Voisine</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pedersen</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Morimoto</surname><given-names>RI</given-names></name> (<year>2010</year>) <article-title>Chaperone networks: tipping the balance in protein folding diseases</article-title>. <source>Neurobiological Diseases</source> <volume>40</volume>: <fpage>12</fpage>–<lpage>20</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Bartz1"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bartz</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>Piantadosi</surname><given-names>CA</given-names></name> (<year>2010</year>) <article-title>Clinical review: oxygen as a signaling molecule</article-title>. <source>Critical Care</source> <volume>14</volume>: <fpage>234</fpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Hamanaka1"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hamanaka</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Chandel</surname><given-names>NS</given-names></name> (<year>2012</year>) <article-title>Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes</article-title>. <source>Trends in Biochemical Sciences</source> <volume>35</volume>: <fpage>505</fpage>–<lpage>513</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Karihtala1"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karihtala</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Soini</surname><given-names>Y</given-names></name> (<year>2007</year>) <article-title>Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies</article-title>. <source>APMIS</source> <volume>115</volume>: <fpage>81</fpage>–<lpage>103</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Gareau1"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gareau</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Lima</surname><given-names>CD</given-names></name> (<year>2010</year>) <article-title>The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition</article-title>. <source>Nature Reviews Molecular Cell Biology</source> <volume>11</volume>: <fpage>861</fpage>–<lpage>871</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-GeissFriedlander1"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Geiss-Friedlander</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Melchior</surname><given-names>F</given-names></name> (<year>2007</year>) <article-title>Concepts in sumoylation: a decade on</article-title>. <source>Nature Reviews Molecular Cell Biology</source> <volume>8</volume>: <fpage>947</fpage>–<lpage>956</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Wilkinson1"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wilkinson</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Henley</surname><given-names>JM</given-names></name> (<year>2010</year>) <article-title>Mechanisms, regulation and consequences of protein SUMOylation</article-title>. <source>Biochemical Journal</source> <volume>428</volume>: <fpage>133</fpage>–<lpage>145</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Moremen1"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moremen</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Tiemeyer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nairn</surname><given-names>AV</given-names></name> (<year>2012</year>) <article-title>Vertebrate protein glycosylation: diversity, synthesis and function</article-title>. <source>Nature Reviews Molecular Cell Biology</source> <volume>13</volume>: <fpage>448</fpage>–<lpage>462</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Schwarz1"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwarz</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Aebi</surname><given-names>M</given-names></name> (<year>2011</year>) <article-title>Mechanisms and principles of N-linked protein glycosylation</article-title>. <source>Current Opinion Structural Biology</source> <volume>21</volume>: <fpage>576</fpage>–<lpage>582</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Kulathu1"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kulathu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Komander</surname><given-names>D</given-names></name> (<year>2012</year>) <article-title>Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages</article-title>. <source>Nature Reviews Molecular Cell Biology</source> <volume>13</volume>: <fpage>508</fpage>–<lpage>523</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Sigismund1"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sigismund</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Polo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Di Fiore</surname><given-names>PP</given-names></name> (<year>2004</year>) <article-title>Signaling through monoubiquitination</article-title>. <source>Curr Top Microbiology Immunology</source> <volume>286</volume>: <fpage>149</fpage>–<lpage>185</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Vertegaal1"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vertegaal</surname><given-names>AC</given-names></name> (<year>2011</year>) <article-title>Uncovering ubiquitin and ubiquitin-like signaling networks</article-title>. <source>Chemical Reviews</source> <volume>111</volume>: <fpage>7923</fpage>–<lpage>7940</lpage>.</mixed-citation></ref>
      <ref id="pcbi.1003016-Chen1"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>JA</given-names></name> (<year>2002</year>) <article-title>A specific protein substrate for a deubiquitinating enzyme: Liquid facets is the substrate of Fat facets</article-title>. <source>Genes and Development</source> <volume>16</volume>: <fpage>289</fpage>–<lpage>294</lpage>.</mixed-citation></ref>
   </ref-list>
</back>
</article>